Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | DTYMK | P23919 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.42 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TPMT | P51580 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31062952 | 1.00 | TSHR (0.56) | TSHRGPR35CYP1A2HSD17B10DTYMK | |
| SCHEMBL13468174 | 0.86 | CYP1A2 (0.47) | TSHRGPR35CYP1A2ERN1MEN1 | |
| SCHEMBL23985882 | 0.85 | CYP1A2 (0.46) | TSHRGPR35CYP1A2ERN1MEN1 | |
| SCHEMBL3939940 | 0.83 | PDGFRB (0.49) | TSHRGPR35CYP1A2ERN1MEN1 | |
| SCHEMBL7055312 | 0.82 | GPR35 (0.54) | TSHRGPR35HSD17B10DTYMKERN1 | |
| SCHEMBL6830067 | 0.82 | TSHR (0.59) | TSHRGPR35CYP1A2DTYMKMEN1 | |
| SCHEMBL31218395 | 0.82 | HSD17B10 (0.61) | TSHRGPR35HSD17B10DTYMKERN1 | |
| SCHEMBL1708885 | 0.82 | HSD17B10 (0.61) | TSHRGPR35HSD17B10DTYMKERN1 | |
| SCHEMBL5201165 | 0.81 | CYP1A2 (0.61) | TSHRGPR35CYP1A2HSD17B10ERN1 | |
| SCHEMBL1446831 | 0.81 | AKR1C2 (0.56) | TSHRGPR35CYP1A2HSD17B10DTYMK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 484 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118406041-A | Tazemetostat synthesis method | 沈阳药科大学 | 2024-07-30 | — | — | CN | claimed |
| CN-116655612-A | Synthetic method and application of EZH2 inhibitor | 王亚男 | 2023-08-29 | — | — | CN | claimed |
| CN-113527275-A | SKLB1039 compound and preparation method and application thereof | 成都师范学院 | 2021-10-22 | — | — | CN | claimed |
| EP-2877462-A1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | Celgene Corporation (US) | 2015-06-03 | — | — | EP | claimed |
| WO-2014018866-A1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION (US) | 2014-01-30 | — | — | WO | claimed |
| US-20140031552-A1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION (US) | 2014-01-30 | — | — | US | claimed |
| CN-122010899-A | Continuous flow preparation method of lenalidomide and derivatives thereof | 深圳连续制药科技有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-12581252-B2 | Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors | RELAY THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250268905-A1 | SALT FORM OF A HUMAN HISTONE METHYLTRANSFERASE EZH2 INHIBITOR | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-08-28 | — | — | US | disclosed |
| US-20250170138-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2025-05-29 | — | — | US | disclosed |
| US-20250109123-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2025-04-03 | — | — | US | disclosed |
| US-12251386-B2 | Salt form of a human histone methyltransferase EZH2 inhibitor | Epizyme, Inc. (US) | 2025-03-18 | — | — | US | disclosed |
| WO-2005084315-A2 | PYRANOINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION OR DISEASE | VIROPHARMA INCORPORATED (US) | 2005-09-15 | — | — | WO | disclosed |
| CN-1655778-A | Methods of treating hepatitis C virus infection using pyranoindole derivatives | WYETH CORP (US) | 2005-08-17 | — | — | CN | disclosed |
| EP-1509225-A1 | METHOD FOR THE USE OF PYRANOINDOLE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | Wyeth (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040082643-A1 | Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus | WYETH (US) | 2004-04-29 | — | — | US | disclosed |
| WO-2003099275-A1 | METHOD FOR THE USE OF PYRANOINDOLE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2003-12-04 | — | — | WO | disclosed |
| EP-0266349-A1 | TRICYCLIC INDOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS MEDICINES. | SCHERING AG (DE) | 1988-05-11 | — | — | EP | disclosed |
| WO-1987000522-A1 | TRICYCLIC INDOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS MEDICINES | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1987-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082643-A1 | Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus | HAVCR2, HCCS, ZC3HAV1 | TSHR 384/4885GPR35 2617/4885CYP1A2 19/4885 |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | MDM2, UBR4, UBE3A | TSHR 1436/4885GPR35 4560/4885CYP1A2 4406/4885 |
| US-20250170138-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | TSHR 3819/4885GPR35 779/4885CYP1A2 15/4885 |
| US-20140031552-A1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | UGT1A1, CYP3A5, CYP3A7 | TSHR 4230/4885GPR35 3144/4885CYP1A2 9/4885 |
| US-20250109123-A1 | COMBINATION THERAPY FOR TREATING CANCER | EZH2, BMI1, HDAC2 | TSHR 3874/4885GPR35 3499/4885CYP1A2 4431/4885 |
| US-12251386-B2 | Salt form of a human histone methyltransferase EZH2 inhibitor | EZH2, DOT1L, NSD1 | TSHR 3985/4885GPR35 4374/4885CYP1A2 4333/4885 |
| US-12581252-B2 | Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors | RORB, ROR1, RORA | TSHR 146/4885GPR35 1736/4885CYP1A2 986/4885 |
| US-20250268905-A1 | SALT FORM OF A HUMAN HISTONE METHYLTRANSFERASE EZH2 INHIBITOR | EZH2, DOT1L, NSD1 | TSHR 3985/4885GPR35 4374/4885CYP1A2 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.